Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NIBR-0213 是S1P1选择性拮抗剂,有抗实验性自身免疫性脑脊髓炎的作用。在 GTPγ35S 试验中,它作用于人和大鼠S1P1的IC50分别为 2.0 nM 和 2.3 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 547 | 现货 | ||
2 mg | ¥ 796 | 现货 | ||
5 mg | ¥ 1,130 | 现货 | ||
10 mg | ¥ 1,760 | 现货 | ||
25 mg | ¥ 3,560 | 现货 | ||
50 mg | ¥ 5,150 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,490 | 现货 |
产品描述 | NIBR-0213, a potent and selective S1P(1) antagonist, has efficacy in experimental autoimmune encephalomyelitis. |
靶点活性 | S1P1:2.0 nM(GTPγ35S,human), S1P1:2.3 nM(GTPγ35S,rat), S1P1:2.5 nM(Ca2+ mobilization), S1P1:8.5 nM(GTPγ35S,mouse) |
体外活性 | In Ca2+?mobilization assays, NIBR-0213 displayed an inhibitory activity on hS1P1?with an IC50?of 2.5?nM whereas it was inactive (IC50?> 10?μM) on S1P2, S1P3, and S1P4. In GTPγ35S assays, NIBR-0213 displayed potent and comparable potency on human and rat S1P1?(IC50?of 2.0?nM and 2.3?nM, respectively), whereas on mouse S1P1?a slightly reduced IC50?of 8.5?nM was?measured. NIBR-0213 showed an ~3,000-fold selectivity against human S1P5?in the GTPγ35S assay (Figure?3A). On S1P4, a weak agonistic activity was detected with an EC50?of 245?nM. Schild plot analysis indicated that NIBR-0213 is a competitive S1P1?antagonist with a calculated Kd?of 0.37?± 0.031?nM[2]. |
体内活性 | NIBR-0213 increased in a dose-dependent manner the leakage of?plasma proteins?into lung parenchyma, as measured by the increase in EBD in lung tissues at 6?hr posttreatment (time of Emax on PBL). A maximum of 4–5-fold EBD increase versus vehicle controls was observed with 0.3?mg/kg. An ED50?of ~0.1?mg/kg could be estimated, i.e., in the range of the ED50?for the effects on PBL counts[2]. NIBR-0213 given orally at 30 mg/kg to rats reduced the PBL counts by 75%–85% within 14 hr and maintained this effect up to 24 hr posttreatment[2]. |
别名 | NIBR 0213 |
分子量 | 464.98 |
分子式 | C27H29ClN2O3 |
CAS No. | 1233332-14-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/ml (118.28 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1506 mL | 10.7532 mL | 21.5063 mL | 53.7658 mL |
5 mM | 0.4301 mL | 2.1506 mL | 4.3013 mL | 10.7532 mL | |
10 mM | 0.2151 mL | 1.0753 mL | 2.1506 mL | 5.3766 mL | |
20 mM | 0.1075 mL | 0.5377 mL | 1.0753 mL | 2.6883 mL | |
50 mM | 0.043 mL | 0.2151 mL | 0.4301 mL | 1.0753 mL | |
100 mM | 0.0215 mL | 0.1075 mL | 0.2151 mL | 0.5377 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NIBR-0213 1233332-14-3 GPCR/G Protein LPL Receptor NIBR 0213 Lysophospholipid Receptor NIBR0213 S1P1 Inhibitor encephalomyelitis autoimmune inhibit inhibitor